Head And Neck Cancer - Pipeline Review, H2 2016 - Global Markets Direct - Market Research

Head And Neck Cancer - Pipeline Review, H2 2016

Head And Neck Cancer - Pipeline Review, H2 2016 - Global Markets Direct - Market Research
Head And Neck Cancer - Pipeline Review, H2 2016
Published Oct 26, 2016
1153 pages — Published Oct 26, 2016
Price US$ 2,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Head And Neck Cancer Pipeline Review, H2 2016, provides an overview of the Head And Neck Cancer (Oncology) pipeline landscape.

Head and Neck Cancer is a cancer that arises in the head or neck region (in the nasal cavity, sinuses, lips, mouth, salivary glands, throat, or larynx). The common symptoms of cancer of the head and neck include persistent pain in the throat, pain or difficulty with swallowing, persistent hoarseness or a change in voice, pain in the ear and bleeding in the mouth or throat. The disease may be controlled by chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Head And Neck Cancer Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Head And Neck Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Head And Neck Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Head And Neck Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 17, 73, 86, 6, 76, 18 and 2 respectively for Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 9, 6, 16 and 3 molecules, respectively for Head And Neck Cancer.

Head And Neck Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Head And Neck Cancer (Oncology).
- The pipeline guide reviews pipeline therapeutics for Head And Neck Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Head And Neck Cancer (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Head And Neck Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all t

  
Source:
Document ID
GMDHC8588IDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents240
  List of Tables365
  List of Figures411
Introduction421
  Global Markets Direct Report Coverage421
Head And Neck Cancer Overview431
Therapeutics Development442
  Pipeline Products for Head And Neck Cancer Overview441
  Pipeline Products for Head And Neck Cancer Comparative Analysis451
Head And Neck Cancer Therapeutics under Development by Companies4614
Head And Neck Cancer Therapeutics under Investigation by Universities/Institutes602
Head And Neck Cancer Pipeline Products Glance624
  Late Stage Products621
  Clinical Stage Products631
  Early Stage Products641
  Unknown Stage Products651
Head And Neck Cancer Products under Development by Companies6621
Head And Neck Cancer Products under Investigation by Universities/Institutes873
Head And Neck Cancer Companies Involved in Therapeutics Development90168
  3SBio Inc.901
  4SC AG911
  AB Science SA921
  AbbVie Inc931
  Accelerated Pharma, Inc.941
  Acceleron Pharma, Inc.951
  Adaptimmune Therapeutics Plc961
  Aduro BioTech, Inc.971
  Advaxis, Inc.981
  Advenchen Laboratories, LLC991
  Affimed GmbH1001
  Alchemia Limited1011
  Altor BioScience Corporation1021
  Ambrx, Inc.1031
  Amgen Inc.1041
  arGEN-X BV1051
  ArQule, Inc.1061
  Aspyrian Therapeutics, Inc.1071
  Astellas Pharma Inc.1081
  AstraZeneca Plc1091
  Atara Biotherapeutics, Inc.1101
  ATLAB Pharma SAS1111
  Aura Biosciences, Inc.1121
  AVEO Pharmaceuticals, Inc.1131
  Bayer AG1141
  Betta Pharmaceuticals Co. Ltd.1151
  Bexion Pharmaceuticals, LLC1161
  Bio-Path Holdings, Inc.1171
  BioDiem Ltd1181
  Biomics Biotechnologies Co., Ltd.1191
  Bionovis SA1201
  BioNTech AG1211
  Biotest AG1221
  Boehringer Ingelheim GmbH1231
  Boston Biomedical, Inc.1241
  Bristol-Myers Squibb Company1251
  Calithera Biosciences, Inc.1261
  CEL-SCI Corporation1271
  Celgene Corporation1281
  Cell Medica Limited1291
  Cellceutix Corporation1301
  Celldex Therapeutics, Inc.1311
  Celprogen, Inc.1321
  Centrose LLC1331
  Corvus Pharmaceuticals, Inc.1341
  Cristal Therapeutics B.V.1351
  Critical Outcome Technologies Inc.1361
  CTI BioPharma Corp.1371
  Daiichi Sankyo Company, Limited1381
  DNJ Pharma, Inc.1391
  Eisai Co., Ltd.1401
  Eleven Biotherapeutics Inc.1411
  Eli Lilly and Company1421
  EntreChem, S.L.1431
  Etubics Corporation1441
  Eureka Therapeutics, Inc.1451
  F. Hoffmann-La Roche Ltd.1461
  Five Prime Therapeutics, Inc.1471
  G&E Herbal Biotechnology Co., Ltd.1481
  Genelux Corporation1491
  GeneSegues Inc1501
  Genexine, Inc.1511
  Genmab A/S1521
  Genticel S.A.1531
  GlaxoSmithKline Plc1541
  Gliknik, Inc.1551
  Glycotope GmbH1561
  Hanmi Pharmaceuticals, Co. Ltd.1571
  Hookipa Biotech AG1581
  Horizon Pharma Plc1591
  Hutchison MediPharma Limited1601
  Ignyta, Inc.1611
  Immunomedics, Inc.1621
  Immunovaccine, Inc.1631
  Immunovative Therapies, Ltd.1641
  Incuron, LLC1651
  Incyte Corporation1661
  Infinity Pharmaceuticals, Inc.1671
  Innate Pharma S.A.1681
  Inovio Pharmaceuticals, Inc.1691
  InteRNA Technologies B.V.1701
  IRX Therapeutics, Inc.1711
  ISA Pharmaceuticals B.V.1721
  Jiangsu Kanion Pharmaceutical Co., Ltd.1731
  Johnson &Johnson1741
  Kite Pharma Inc1751
  Kolltan Pharmaceuticals, Inc.1761
  Kura Oncology, Inc.1771
  Laboratoires Pierre Fabre SA1781
  Lakewood-Amedex Inc1791
  Loxo Oncology, Inc.1801
  Lytix Biopharma AS1811
  Mabion SA1821
  Mabtech Limited1831
  MacroGenics, Inc.1841
  Marsala Biotech Inc.1851
  Mateon Therapeutics Inc1861
  MaxiVAX SA1871
  Meabco A/S1881
  MedImmune, LLC1891
  Merck &Co., Inc.1901
  Merck KGaA1911
  Merrimack Pharmaceuticals, Inc.1921
  Millennium Pharmaceuticals Inc1931
  Mirati Therapeutics Inc.1941
  Molecular Partners AG1951
  Moleculin Biotech Inc1961
  Molplex Ltd.1971
  NanoCarrier Co., Ltd.1981
  Natco Pharma Limited1991
  Neonc Technologies Inc2001
  Northwest Biotherapeutics, Inc.2011
  Novartis AG2021
  Omnitura Therapeutics Inc.2031
  Oncobiologics, Inc.2041
  Oncolys BioPharma Inc2051
  Oncolytics Biotech Inc.2061
  Onconova Therapeutics, Inc.2071
  OncoSec Medical Incorporated2081
  Ono Pharmaceutical Co., Ltd.2091
  Oryx GmbH &Co. KG2101
  Panacea Biotec Limited2111
  PCI Biotech Holding ASA2121
  PDS Biotechnology Corporation2131
  Pfizer Inc.2141
  Pharma Mar, S.A.2151
  Pique Therapeutics2161
  PlantForm Corporation2171
  Plexxikon Inc.2181
  PNP Therapeutics, Inc.2191
  Profectus BioSciences, Inc.2201
  ProNAi Therapeutics, Inc.2211
  Provectus Biopharmaceuticals, Inc.2221
  R-Pharm2231
  Redx Pharma Plc2241
  Reliance Life Sciences Pvt. Ltd.2251
  Sanofi2261
  Sapvax2271
  Sareum Holdings Plc2281
  Selecta Biosciences, Inc.2291
  Shanghai Henlius Biotech Co., Ltd.2301
  Shenzen SiBiono GeneTech Co., Ltd.2311
  Shionogi &Co., Ltd.2321
  Silence Therapeutics Plc2331
  Sillajen Biotherapeutics2341
  Sinil Pharmaceutical Co., Ltd2351
  SuviCa Inc.2361
  Symphogen A/S2371
  SynCore Biotechnology Co., Ltd.2381
  Taiwan Liposome Company, Ltd.2391
  Takara Bio Inc.2401
  Takis S.r.l.2411
  Tara Immuno-Oncology Therapeutics LLC2421
  Tessa Therapeutics Pte Ltd2431
  Theravectys SA2441
  Tolero Pharmaceuticals, Inc.2451
  TyrNovo Ltd.2461
  UbiVac, LLC2471
  Vaccibody AS2481
  VasGene Therapeutics, Inc.2491
  Vault Pharma Inc.2501
  Vaxeal Holding SA2511
  VentiRx Pharmaceuticals, Inc.2521
  Virttu Biologics Limited2531
  VLPbio2541
  VM Discovery, Inc.2551
  Vyriad Inc2561
  Yabao Pharmaceutical Group Co., Ltd.2571
Head And Neck Cancer Therapeutics Assessment25835
  Assessment by Monotherapy Products2581
  Assessment by Combination Products2591
  Assessment by Target26014
  Assessment by Mechanism of Action27415
  Assessment by Route of Administration2892
  Assessment by Molecule Type2912
Drug Profiles293821
  4SC-205 Drug Profile2932
  ABBV-221 Drug Profile2951
  acalabrutinib Drug Profile2963
  AdIL-24 Drug Profile2992
  ADUS-100 Drug Profile3013
  afatinib dimaleate Drug Profile30413
  AFM-22 Drug Profile3171
  AFM-24 Drug Profile3181
  AlloVax Drug Profile3192
  alpelisib Drug Profile3213
  ALT-803 Drug Profile3243
  amcasertib Drug Profile3272
  AMG-319 Drug Profile3292
  Antibodies to Inhibit FRMD4A for Oncology Drug Profile3311
  Antisense Oligonucleotide to Target EGFR for Head and Neck Cancer Squamous Cell Carcinoma Drug Profile3321
  Antisense RNAi Oligonucleotide for Nasopharyngeal Cancer Drug Profile3331
  Antisense RNAi Oligonucleotide to Inhibit Mutated Ataxia Telangiectasia Gene for Head and Neck Cancer Drug Profile3341
  apatinib Drug Profile3353
  ARGX-110 Drug Profile3384
  atezolizumab Drug Profile34214
  ATL-101 Drug Profile3562
  Atu-027 Drug Profile3584
  AV-203 Drug Profile3623
  avelumab Drug Profile3655
  axalimogene filolisbac Drug Profile37016
  AY-4 Drug Profile3861
  azacitidine Drug Profile3875
  AZD-1775 Drug Profile3923
  AZD-6738 Drug Profile3951
  AZD-9150 Drug Profile3963
  baltaleucel-T Drug Profile3992
  BAY-1163877 Drug Profile4011
  BB-002 Drug Profile4021
  Biologic for Oncology Drug Profile4031
  BMS-986016 Drug Profile4042
  BMX-001 Drug Profile4061
  BNV-003 Drug Profile4071
  BP-1001 Drug Profile4086
  BPC-1 Drug Profile4141
  buparlisib hydrochloride Drug Profile4155
  BXQ-350 Drug Profile4202
  cabazitaxel Drug Profile4222
  cabazitaxel Drug Profile4241
  cabiralizumab Drug Profile4253
  capmatinib Drug Profile4283
  CB-1158 Drug Profile4312
  CBL-0137 Drug Profile4334
  CBX-1 Drug Profile4371
  CCP-040 Drug Profile4381
  CCT-244747 Drug Profile4392
  CCV-3612552 Drug Profile4411
  Cellular Immunotherapy for HPV Associated Cancers Drug Profile4421
  Cellular Immunotherapy for Multiple Sclerosis Drug Profile4431
  Cellular Immunotherapy for Nasopharyngeal Cancer Drug Profile4441
  Cellular Immunotherapy for Oncology Drug Profile4453

Table Of Contents

Global Markets Direct - Market Research—Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.

About the Author


Cite this Report

  
MLA:
Global Markets Direct - Market Research. "Head And Neck Cancer - Pipeline Review, H2 2016" Oct 26, 2016. Alacra Store. May 04, 2025. <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Head-And-Neck-Cancer-Pipeline-Review-H2-2016-2088-16703>
  
APA:
Global Markets Direct - Market Research. (2016). Head And Neck Cancer - Pipeline Review, H2 2016 Oct 26, 2016. New York, NY: Alacra Store. Retrieved May 04, 2025 from <http://www.alacrastore.com/storecontent/Global-Markets-Direct-Market-Research/Head-And-Neck-Cancer-Pipeline-Review-H2-2016-2088-16703>
  
US$ 2,500.00
$  £  
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.